TY - JOUR
T1 - Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes
AU - Leong, Darryl P
AU - Fradet, Vincent
AU - Niazi, Tamim
AU - Selvanayagam, Joseph B
AU - Sabbagh, Robert
AU - Higano, Celestia S
AU - Agapay, Steven
AU - Rangarajan, Sumathy
AU - Mian, Rajibul
AU - Nakashima, Carlos A K
AU - Mousavi, Negareh
AU - Brown, Ian
AU - Valle, Felipe H
AU - Lavallée, Luke T
AU - Shayegan, Bobby
AU - Ng, Kelvin K H
AU - Gopaul, Darin D
AU - Cavalli, Germano D
AU - Saavedra, Sonia
AU - Lopez-Lopez, Jose P
AU - Freitas de Souza, Cristiano
AU - Duceppe, Emmanuelle
AU - Avezum Oliveira, Lívia F
AU - Guha, Avirup
AU - Gomez-Mesa, Juan Esteban
AU - Eduardo Silva Móz, Luis
AU - Violette, Philippe D
AU - Avezum, Álvaro
AU - Oliveira, Gustavo B F
AU - Kann, Ariel G
AU - Walter, Edilson
AU - Dusilek, Cesar O L
AU - Villareal Trujillo, Nicolas
AU - Beato, Patricia
AU - Hajjar, Ludhmila A
AU - Luke, Patrick P W
AU - Schlabendorff, Eduardo
AU - Sarid, David
AU - Pinthus, Jehonathan
PY - 2024/10
Y1 - 2024/10
N2 - Background: There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes. Objectives: The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures. Methods: This international, prospective cohort study included 3,967 patients with PC diagnosed in the prior 12 months or being treated with ADT for the first time. Median follow-up duration was 2.3 years. Results: Participants’ mean age was 68.5 years, and 1,731 (43.6%) were exposed to ADT. ADT was associated with a 1.6% increase in weight, a 2.2% increase in waist circumference, a 1.6% increase in hip circumference, a 0.1% increase in waist-to-hip ratio, a 27.4% reduction in handgrip strength, and a 0.1% decrease in gait speed. High waist circumference and low handgrip strength were associated with adverse cardiovascular outcomes. Adjusting for age, education, race, tobacco and alcohol use, physical activity, cardiovascular disease, glomerular filtration rate, and ADT use, waist circumference above the highest quartile (110 cm) and handgrip strength below the lowest quartile (29.5 kg) were associated with higher likelihoods of a future cardiovascular event, with respective HRs of 1.40 (95% CI: 1.03-1.90; P = 0.029) and 1.59 (95% CI: 1.14-2.22; P = 0.006). Conclusions: ADT was associated with increased adiposity and reduced strength over 12-month follow-up. High waist circumference and low baseline strength were associated with future adverse cardiovascular outcomes.
AB - Background: There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes. Objectives: The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures. Methods: This international, prospective cohort study included 3,967 patients with PC diagnosed in the prior 12 months or being treated with ADT for the first time. Median follow-up duration was 2.3 years. Results: Participants’ mean age was 68.5 years, and 1,731 (43.6%) were exposed to ADT. ADT was associated with a 1.6% increase in weight, a 2.2% increase in waist circumference, a 1.6% increase in hip circumference, a 0.1% increase in waist-to-hip ratio, a 27.4% reduction in handgrip strength, and a 0.1% decrease in gait speed. High waist circumference and low handgrip strength were associated with adverse cardiovascular outcomes. Adjusting for age, education, race, tobacco and alcohol use, physical activity, cardiovascular disease, glomerular filtration rate, and ADT use, waist circumference above the highest quartile (110 cm) and handgrip strength below the lowest quartile (29.5 kg) were associated with higher likelihoods of a future cardiovascular event, with respective HRs of 1.40 (95% CI: 1.03-1.90; P = 0.029) and 1.59 (95% CI: 1.14-2.22; P = 0.006). Conclusions: ADT was associated with increased adiposity and reduced strength over 12-month follow-up. High waist circumference and low baseline strength were associated with future adverse cardiovascular outcomes.
KW - adiposity
KW - androgen deprivation therapy
KW - cardiovascular
KW - muscle strength
KW - obesity
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85204677908&partnerID=8YFLogxK
U2 - 10.1016/j.jaccao.2024.07.011
DO - 10.1016/j.jaccao.2024.07.011
M3 - Article
AN - SCOPUS:85204677908
SN - 2666-0873
VL - 6
SP - 761
EP - 771
JO - JACC: CardioOncology
JF - JACC: CardioOncology
IS - 5
ER -
